Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Sanofi aims to boost competition in the atopic dermatitis market, following Dupixent's success, with new treatments like SAR444656 and amlitelimab in development.

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

• Topical treatments: Over-the-counter 1% hydrocortisone cream can help with mild flare-ups. For more severe cases, pediatricians may prescribe stronger topical steroids or calcineurin inhibitors.

Shaperon secures phase 2 trials for atopic dermatitis treatment Nugel after positive review Shaperon obtains approval for ...

Tofacitinib etocomil ointment 1.0% has proven effective in treating mild-to-moderate atopic dermatitis, achieving significant ...

The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...